13

Feb2020

PDCI Analysis Estimates Impact of PMPRB Draft Guidelines to be up to $41.8 Billion

Following the publication of the PMPRB Draft Guidelines on Nov 21, 2019, PDCI undertook an analysis to critically assess the impact of the PMPRB regulatory changes published in August 2019, as proposed to be implemented in the Draft Guidelines. Top-Line Summary The PMPRB regulatory changes and Draft ... Read More

29

Jan2020

PDCI’s New Associate Director, HTA and Clinical Evaluation

PDCI is excited to announce the promotion of Andrea Lau to the position of Associate Director, HTA and Clinical Evaluation. Andrea has been with PDCI for over 3 years, and in that time has been invaluable ... Read More

15

Jan2020

Status Summary of Innovative Medicine pCPA Negotiations as of December 31, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA ... Read More

14

Jan2020

PMPRB and “Zero-dollar” Sales

W. Neil Palmer In its December 2019 NEWSletter[1], the Patented Medicine Prices Review Board (PMPRB) is “reminding” patentees that they are required under the Patent Act (the Act) and the Patented Medicines Regulations (the Regulations) to file all zero-dollar sales, referring specifically to free goods. This “reminder” is troubling ... Read More

13

Jan2020

CADTH Releases Pharmaceutical Reviews Update – Issue 12

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.  CADTH released new updates to economic Category 1 Requirements ... Read More

18

Dec2019

Happy Holidays from PDCI Market Access!

10

Dec2019

Status Summary of Innovative Medicine pCPA Negotiations as of November 30, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.             ... Read More

27

Nov2019

CADTH Releases Pharmaceutical Reviews Update – Issue 11

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH website. This CADTH update primarily ... Read More

26

Nov2019

PDCI Market Access: PMPRB Reforms Briefing and Strategy Sessions (Toronto and Montreal)

REGISTRATION IS OPEN! Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members ... Read More

22

Nov2019

Status Summary of Innovative Medicine pCPA Negotiations as of October 31, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA Activity Since ... Read More